company background image
APTX

Aptinyx NasdaqGS:APTX Stock Report

Last Price

US$0.35

Market Cap

US$23.8m

7D

-41.4%

1Y

-84.1%

Updated

18 Aug, 2022

Data

Company Financials +
APTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

APTX Stock Overview

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.

Aptinyx Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aptinyx
Historical stock prices
Current Share PriceUS$0.35
52 Week HighUS$3.76
52 Week LowUS$0.33
Beta1.24
1 Month Change-46.50%
3 Month Change-40.70%
1 Year Change-84.09%
3 Year Change-88.76%
5 Year Changen/a
Change since IPO-98.26%

Recent News & Updates

Aug 12

Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study

Aptinyx (NASDAQ:APTX) said its oral medicine NYX-2925 did not show statistically significant separation from placebo in reducing pain, failing to meet the main goal of a phase 2b trial. The study evaluated 2 doses (50mg-100mg) of the drug versus placebo in ~300 patients with fibromyalgia — a disorder that causes widespread musculoskeletal pain. The main goal was the change from baseline in average daily pain as reported on the 0-to-10 numeric rating scale (NRS) during week 12 of the study. The company said that both doses did not show statistically significant separation from placebo. Patients on NYX-2925 at both doses showed a trend toward clinically meaningful improvement in pain, and some secondary goals, versus placebo by week 4. However, by week 12, the placebo group improved such that, although NYX-2925 remained numerically better, the separation was not clinically meaningful, Aptinyx said in an Aug. 12 press release. NYX-2925 was well tolerated in the study, and no concerning safety issues were seen, according to the company. Aptinyx added that detailed data from the study continue to be evaluated.

Shareholder Returns

APTXUS BiotechsUS Market
7D-41.4%-2.0%1.4%
1Y-84.1%-22.2%-8.4%

Return vs Industry: APTX underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: APTX underperformed the US Market which returned -9% over the past year.

Price Volatility

Is APTX's price volatile compared to industry and market?
APTX volatility
APTX Average Weekly Movement17.5%
Biotechs Industry Average Movement12.4%
Market Average Movement7.6%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: APTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: APTX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201540Andy Kiddhttps://www.aptinyx.com

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson’s disease cognitive impairment.

Aptinyx Inc. Fundamentals Summary

How do Aptinyx's earnings and revenue compare to its market cap?
APTX fundamental statistics
Market CapUS$23.82m
Earnings (TTM)-US$78.33m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$55.44m
Gross Profit-US$55.44m
Other ExpensesUS$22.89m
Earnings-US$78.33m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.16
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio39.4%

How did APTX perform over the long term?

See historical performance and comparison